Product Name:
TAK1-pS439
Product Number:
ab-pk824
Target Full Name: TGF-beta-activated protein-serine kinase 1; Mitogen-activated protein kinase kinase kinase 7
Target Alias: M3K7; MAP3K7; MEKK7; TGF1a; TGF-beta-activated kinase 1; TGF1a; ENSG00000135341
Product Type Specific: TAK1 (MAP3K7) protein kinase phosphosite-specific antibody
Antibody Code: PK824
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S439
Protein UniProt: O43318
Protein SigNET: TAK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human TAK1 sequence peptide Cat. No.: PE-04APV90
Antibody Immunogen Sequence: RRR(pS)IQD(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R436 to D442; in the C-terminal half of the protein. S439 phosphorylation induces interaction with IKKG. This is the major in vivo phosphorylation site in TAK1 based on ≥146 mass spectrometry reports recorded in PhosphoSitePlus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rat | Mouse | Platypus | Zebra fish.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 67-85 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in T98G cells.
Related Product 1: TAK1 (436-442) pS439 antibody blocking peptide (Cat. No.: PE-04APV90)
Related Product 2: TAK1-CT (TAK1-4) pan-specific antibody (Cat. No.: AB-NK175-3)
Related Product 3: TAK1-pS439 phosphosite-specific antibody (Cat. No.: AB-PK824)
Related Product 4: TAK1-pT184+pT187 phosphosite-specific antibody (Cat. No.: AB-PK825)
Scientific Background: TAK1 (MAP3K7, MEKK7) is a protein-serine/threonine kinase of the TKL group and MLK family. TAK1 is activated by proinflammatory cytokines and in response to physical/chemical stress, including UVR, osmotic- and oxidative stress. It is a mediator of TRAF6 and TGF-beta signal transduction, and activates IKBKB and MAPK8 in response to TRAF6 signalling. It also stimulates NFκB activation and activation of the p38 MAPK (MAPK8) pathway. It is responsible for controlling a variety of cell functions such as transcription and apoptosis. It regulates hepatic cell survival and carcinogenesis. TAK1 is important for TGF-beta1 regulation of MMP9 and the metastatic potential of certain breast cancer cell lines. It is activated by phosphorylation at T178, T184, T187 and S192. It is also activated by K63-linked polyubiquitination. TAK1 plays a role in tumour initiation, progression, and metastasis such as in breast cancer as a tumour inducer or tumour suppression depending on the cancer. This description may include information annotated by UniProt and/or Google AI.